Turbocharge CAR-T Manufacturing: Industrializing Cell Therapy With Perfusion

As allogeneic CAR‑T programs move toward commercial reality, manufacturing strategies must deliver speed, scale, and consistency without compromising product quality. Explore how intensified perfusion processes can meet those demands. You’ll see how high‑density CAR‑T expansion in stirred‑tank bioreactors supports rapid dose generation using serum‑free media and tightly controlled perfusion strategies. The discussion highlights predictive scale‑down modeling from Ambr® 250 STR to 2 L, enabled by matched volumetric power input, alongside real‑time viable cell monitoring using multi‑frequency capacitance. Downstream considerations are also addressed, including automated harvest integration, achieving greater than 90% recovery.

Gain practical insights into reducing manufacturing timelines, increasing yields, and building a more scalable, economically viable CAR‑T production platform.